PMD Psychemedics Corp.

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas

ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing.

The move to Dallas underscores Psychemedics’ commitment to expanding operations, fostering innovation, and better serving its diverse clientele globally. This strategic relocation aims to further streamline operations while ensuring uninterrupted, top-tier services for clients.

Brian Hullinger, Chief Executive Officer and President of Psychemedics Corporation, expressed confidence in the move, stating, “Our shift to Dallas signifies a pivotal step in our growth strategy. This relocation bolsters our ability to innovate and reinforces our unwavering dedication to delivering exceptional service to our clients.”

The new address for Psychemedics Corporation headquarters is:

5220 Spring Valley Road

Ste 230

Dallas, TX 75254

All contact information, including phone numbers and email addresses, remains unchanged.

For more information about Psychemedics Corporation and its innovative hair testing solutions, please visit .

About Psychemedics 

Psychemedics Corporation is a leading global provider of innovative hair testing for drugs of abuse. With a commitment to accuracy and reliability, the company offers cutting-edge drug testing solutions. Psychemedics Corporation is dedicated to providing valuable insights and maintaining the highest standards in substance abuse testing.

Investor Relations:

Phone: 978-206-8220

Email:  



EN
02/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Psychemedics Corp.

 PRESS RELEASE

Psychemedics Corporation Reports 2023 Financial Results

Psychemedics Corporation Reports 2023 Financial Results DALLAS, March 28, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, announced today financial results for the year ended December 31, 2023. “2023 proved to be another challenging year due to the negative impact of major economic forces. The labor shortage continues and remains unprecedented in its severity and duration, having an adverse impact on our clients. Despite these challenges, my confidence in our potential continues to increase. As cost reducti...

 PRESS RELEASE

Psychemedics Recognized as a Top 10 Employee Health Testing Services P...

Psychemedics Recognized as a Top 10 Employee Health Testing Services Provider Dallas, TX, March 21, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in drug testing using hair analysis, is proud to announce its recognition as one of the Top 10 Employee Health Testing Services Providers for 2024 by ManageHR. This prestigious accolade highlights Psychemedics’ commitment to excellence and innovation in the field of employee health testing. ManageHR’s annual list recognizes companies that excel in providing cutting-edge solutions and services for employee heal...

 PRESS RELEASE

Psychemedics Corporation Announces Relocation of Headquarters to Dalla...

Psychemedics Corporation Announces Relocation of Headquarters to Dallas, Texas ACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, proudly announces the relocation of its corporate headquarters from Acton, Massachusetts, to Dallas, Texas, while reaffirming its unwavering dedication to delivering exceptional service and maintaining the highest standards in hair drug testing. The move to Dallas underscores Psychemedics’ commitment to expanding operations, fostering innovation, and better serving its diverse cliente...

 PRESS RELEASE

Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance

Psychemedics Corporation Appoints Daniella Mehalik as VP - Finance ACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she will play a pivotal role in st...

 PRESS RELEASE

Psychemedics Corporation Reports Third Quarter 2023 Financial Results

Psychemedics Corporation Reports Third Quarter 2023 Financial Results ACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, today announced financial results for the third quarter ended September 30, 2023. The Company’s revenue for the quarter ended September 30, 2023, was $5.7 million versus $6.5 million for the quarter ended September 30, 2022, a decrease of 12%. Net loss for the quarter ended September 30, 2023, was $(2.1 million) or $(0.36) per diluted share, versus net loss of $(97,000) or $(0.0...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch